Sino Biopharmaceutical Ltd ADR SBHMY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $7.41
- Day Range
- $7.20–7.20
- 52-Week Range
- $6.69–11.18
- Bid/Ask
- $5.65 / $6.10
- Market Cap
- $6.77 Bil
- Volume/Avg
- 858 / 2,493
Key Statistics
- Price/Earnings (Normalized)
- 18.87
- Price/Sales
- 1.81
- Dividend Yield (Trailing)
- 2.84%
- Dividend Yield (Forward)
- 2.84%
- Total Yield
- 3.57%
Company Profile
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP’s current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 25,806
- Website
- https://www.sinobiopharm.com
Competitors
Valuation
|
Metric
|
SBHMY
|
01093
|
01801
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.87 | 9.94 | — |
Price/Book Value | 1.57 | 1.91 | 3.93 |
Price/Sales | 1.81 | 2.00 | 7.65 |
Price/Cash Flow | 9.41 | 13.26 | — |
Price/Earnings
SBHMY
01093
01801
Financial Strength
|
Metric
|
SBHMY
|
01093
|
01801
|
|---|---|---|---|
Quick Ratio | 0.93 | 2.40 | 3.21 |
Current Ratio | 1.00 | 2.70 | 3.96 |
Interest Coverage | 9.68 | 273.66 | −14.05 |
Quick Ratio
SBHMY
01093
01801
Profitability
|
Metric
|
SBHMY
|
01093
|
01801
|
|---|---|---|---|
Return on Assets (Normalized) | 3.98% | — | −9.10% |
Return on Equity (Normalized) | 8.61% | — | −15.75% |
Return on Invested Capital (Normalized) | 5.64% | — | −12.17% |
Return on Assets
SBHMY
01093
01801
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dthddccdx | Zxhx | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zgwgfrx | Rptjr | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jwxltqzg | Mjsrrp | $98.1 Bil | |
MRNA
| Moderna Inc | Pfhhqgxp | Vxvm | $39.1 Bil | |
ARGX
| argenx SE ADR | Qhjsglk | Mcrd | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Ndfkwhxd | Fxjcb | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rxhyqbvx | Vmpyg | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pyphxvhgw | Cjstmd | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yrvnysjkt | Mdhkcry | $12.5 Bil | |
INCY
| Incyte Corp | Kywzkbxnw | Ctwyb | $11.9 Bil |